CY1122604T1 - Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης - Google Patents
Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασηςInfo
- Publication number
- CY1122604T1 CY1122604T1 CY20201100026T CY201100026T CY1122604T1 CY 1122604 T1 CY1122604 T1 CY 1122604T1 CY 20201100026 T CY20201100026 T CY 20201100026T CY 201100026 T CY201100026 T CY 201100026T CY 1122604 T1 CY1122604 T1 CY 1122604T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mcg
- dose
- equivalent
- angiotasin
- hypotension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917576P | 2013-12-18 | 2013-12-18 | |
| US201461955706P | 2014-03-19 | 2014-03-19 | |
| PCT/US2014/071186 WO2015095535A1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii alone or in combination for the treatment of hypotension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122604T1 true CY1122604T1 (el) | 2021-03-12 |
Family
ID=53367119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100026T CY1122604T1 (el) | 2013-12-18 | 2020-01-13 | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US9220745B2 (enExample) |
| EP (2) | EP3607962B1 (enExample) |
| JP (4) | JP6824739B2 (enExample) |
| KR (4) | KR20230051721A (enExample) |
| CN (4) | CN111920939A (enExample) |
| AU (3) | AU2014364528C1 (enExample) |
| BR (1) | BR112016013961A2 (enExample) |
| CA (1) | CA2933601A1 (enExample) |
| CY (1) | CY1122604T1 (enExample) |
| DK (2) | DK3607962T3 (enExample) |
| EA (1) | EA037823B1 (enExample) |
| ES (2) | ES2771749T3 (enExample) |
| FI (1) | FI3607962T3 (enExample) |
| HR (2) | HRP20251406T1 (enExample) |
| HU (1) | HUE047062T2 (enExample) |
| IL (1) | IL246162B (enExample) |
| LT (2) | LT3607962T (enExample) |
| MX (2) | MX380968B (enExample) |
| NZ (1) | NZ721089A (enExample) |
| PL (2) | PL3607962T3 (enExample) |
| PT (2) | PT3607962T (enExample) |
| RS (2) | RS67626B1 (enExample) |
| SI (2) | SI2986308T1 (enExample) |
| SM (2) | SMT202000018T1 (enExample) |
| WO (1) | WO2015095535A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| LT3607962T (lt) | 2013-12-18 | 2026-01-12 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Vien tik angiotenzinas ii arba derinyje, skirtas hipotenzijos gydymui |
| TWI754225B (zh) * | 2014-07-08 | 2022-02-01 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| US9919022B2 (en) | 2015-03-20 | 2018-03-20 | Arthur J. ATKINSON, JR. | Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
| BR112018013852A2 (pt) * | 2016-01-07 | 2018-12-18 | La Jolla Pharmaceutical Company | métodos de administração de vasopressores |
| BR112018013847A2 (pt) * | 2016-01-07 | 2018-12-18 | La Jolla Pharma Co | métodos para administrar a angiotensina ii |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| US20190183962A1 (en) * | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
| US20250366467A1 (en) * | 2022-06-15 | 2025-12-04 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
| WO2024129057A1 (en) * | 2022-12-12 | 2024-06-20 | Proletariat Therapeutics, Inc. | Methods of treating cardiac injury |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
| US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| WO2002098906A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| US7785566B2 (en) | 2003-11-06 | 2010-08-31 | Ge Healthcare, Inc. | Pharmaceutical compounds |
| NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
| FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
| WO2007040636A1 (en) | 2005-09-29 | 2007-04-12 | Fibrogen, Inc. | Methods for reducing blood pressure |
| EP1971358A4 (en) * | 2005-12-30 | 2010-05-26 | Florey Howard Inst | Methods of Treatment |
| US20070293552A1 (en) | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| CN101795675A (zh) | 2006-11-17 | 2010-08-04 | 达沃尔泰拉公司 | 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送 |
| WO2009009907A1 (en) * | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| MX2011005672A (es) | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
| US9572856B2 (en) * | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| AU2011279144A1 (en) | 2010-07-14 | 2013-01-24 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists |
| AU2014256944B2 (en) | 2013-04-26 | 2019-06-27 | La Jolla Pharma, Llc | Compositions and methods for treating renal failure |
| LT3607962T (lt) | 2013-12-18 | 2026-01-12 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Vien tik angiotenzinas ii arba derinyje, skirtas hipotenzijos gydymui |
| US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
| TWI754225B (zh) | 2014-07-08 | 2022-02-01 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| BR112018013852A2 (pt) | 2016-01-07 | 2018-12-18 | La Jolla Pharmaceutical Company | métodos de administração de vasopressores |
| BR112018013847A2 (pt) | 2016-01-07 | 2018-12-18 | La Jolla Pharma Co | métodos para administrar a angiotensina ii |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| US20190183962A1 (en) | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
-
2014
- 2014-12-18 LT LTEP19197866.7T patent/LT3607962T/lt unknown
- 2014-12-18 FI FIEP19197866.7T patent/FI3607962T3/fi active
- 2014-12-18 HR HRP20251406TT patent/HRP20251406T1/hr unknown
- 2014-12-18 PL PL19197866.7T patent/PL3607962T3/pl unknown
- 2014-12-18 EP EP19197866.7A patent/EP3607962B1/en active Active
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
- 2014-12-18 DK DK19197866.7T patent/DK3607962T3/da active
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Ceased
- 2014-12-18 PT PT191978667T patent/PT3607962T/pt unknown
- 2014-12-18 SM SM20200018T patent/SMT202000018T1/it unknown
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 KR KR1020247034828A patent/KR20240154702A/ko active Pending
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en not_active Ceased
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko not_active Ceased
- 2014-12-18 MX MX2016008108A patent/MX380968B/es unknown
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 RS RS20251135A patent/RS67626B1/sr unknown
- 2014-12-18 CN CN202411722811.2A patent/CN119700926A/zh active Pending
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 SM SM20250427T patent/SMT202500427T1/it unknown
- 2014-12-18 ES ES19197866T patent/ES3055611T3/es active Active
- 2014-12-18 SI SI201432120T patent/SI3607962T1/sl unknown
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active Active
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 HR HRP20200009TT patent/HRP20200009T1/hr unknown
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en not_active Abandoned
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja not_active Withdrawn
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
-
2024
- 2024-09-18 AU AU2024219851A patent/AU2024219851A1/en active Pending
-
2025
- 2025-05-09 JP JP2025078759A patent/JP2025114753A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| MX380968B (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| CY1124596T1 (el) | Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση | |
| CY1124759T1 (el) | Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης | |
| EA201690212A1 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| MD20170025A2 (ro) | Tratamente terapeutice pe bază de anamorelin | |
| CY1120906T1 (el) | Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| EA201891968A1 (ru) | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства | |
| MX2017012926A (es) | Inhibidores y sus usos. | |
| EA202091873A2 (ru) | Способы лечения гипотонии | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| MX2016003525A (es) | Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento. | |
| MX2018013468A (es) | Metodos y formulaciones para el tratamiento y/o prevencion de trastornos relacionados con la sangre. | |
| MX374354B (es) | Método de curación de heridas. | |
| MX373322B (es) | Tratamiento de los síntomas asociados a terapia privación de andrógenos. | |
| MX2019014354A (es) | Metodos para identificar nuevos regimenes de dosificacion. | |
| JOP20210347A1 (ar) | طرق لعلاج فيروس نقص المناعة البشرية | |
| MX2018004779A (es) | Uso terapeutico de una solucion oftalmica acuosa esteril. | |
| CY1125036T1 (el) | Μυκητοκτονος συνθεση αποτελεσματικη κατα του μηκυτα altenaria στα εσπεριδοειδη | |
| EA202092463A1 (ru) | Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии |